Trospium: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 22, 2026🚩 Report this page

Trospium

Drugs For Urinary Frequency and Incontinence

US FDAGB MHRA

Drug class: Drugs For Urinary Frequency and Incontinence
Availability: Prescription only
Routes: Oral
Markets covered: 2
Products on record: 8

G04BDDrugs For Urinary Frequency and Incontinence

Overview

Trospium is an active pharmaceutical ingredient in the Drugs For Urinary Frequency and Incontinence group (G04BD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
US United States	FDA	4	April 14, 2026
GB United Kingdom	MHRA	4	May 22, 2026

USUnited States· FDA

4 products

Uses

USOfficial regulatory label· revised December 19, 2024[1]

1 INDICATIONS & USAGE Trospium chloride tablets is a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets is a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

How to take

GBUnited Kingdom· MHRA

4 products

Uses

GBOfficial regulatory label· revised May 23, 2025[2]

g. idiopathic or neurologic detrusor overactivity).

How to take

GBOfficial regulatory label

Drug interactions

Known interactions involving Trospium. Select one for details. This list is informational and not a complete interaction checker.

Potassium Chloride Potassium Citrate Topiramate Zonisamide Acebutolol Acetylcholine Aclidinium Acrivastine Acyclovir Alfentanil Amantadine Ambenonium Amitriptyline Amoxapine Arbutamine Aripiprazole Asenapine Atenolol Atropine Azatadine Benzhydrocodone Betaxolol Bethanechol Biperiden Bisoprolol Botulinum Toxin Type A Botulinum Toxin Type B Brexpiprazole Brompheniramine Buprenorphine Butorphanol Carbamoylcholine Carbinoxamine Cariprazine Carteolol Carvedilol Cevimeline Chlorcyclizine Chlorpheniramine Chlorpromazine Cidofovir Cimetidine Clemastine Clidinium Clomipramine Clozapine Codeine Cyclizine Cyclobenzaprine Cyproheptadine Darifenacin Demecarium Desipramine Dexbrompheniramine Dezocine Dicyclomine Digoxin Dihydrocodeine Dimenhydrinate Diphenhydramine Disopyramide Donepezil Doxepin Doxylamine Edrophonium Eluxadoline Ethanol Fentanyl Fesoterodine Flavoxate Flecainide Fluphenazine Galantamine Ganciclovir Glycopyrronium Guanidine Haloperidol Hydrocodone Hydromorphone Hydroxyzine Hyoscyamine Iloperidone Imipramine Ipratropium Isoflurophate Ketoconazole Labetalol Levodopa Levorphanol Loperamide Loxapine Lumateperone Lurasidone Maprotiline Meclizine Memantine Mepenzolate Meperidine Mesoridazine Metformin Methadone Methdilazine Methotrimeprazine Methscopolamine Metoclopramide Metoprolol Midodrine Mirabegron Molindone Morphine Nadolol Nalbuphine Nebivolol Neostigmine Nortriptyline Olanzapine Oliceridine Opium Orphenadrine Oxybutynin Oxycodone Oxymorphone Paliperidone Pancuronium Penbutolol Pentazocine Perphenazine Phenindamine Phenyltoloxamine Physostigmine Pilocarpine Pimozide Pindolol Pramlintide Procainamide Prochlorperazine Procyclidine Promazine Promethazine Propantheline Propiomazine Propoxyphene Propranolol Protriptyline Prucalopride Pyridostigmine Pyrilamine Quetiapine Quinidine Ranitidine Remifentanil Revefenacin Risperidone Rivastigmine Scopolamine Solifenacin Sotalol Sufentanil Tacrine Tapentadol Thiethylperazine Thioridazine Thiothixene Timolol Tiotropium Tolterodine Tramadol Triamterene Trifluoperazine Triflupromazine Trihexyphenidyl Trimeprazine Trimipramine Tripelennamine Triprolidine Umeclidinium Valacyclovir Valganciclovir Vancomycin Vibegron Ziprasidone Acetaminophen Bendroflumethiazide Benzthiazide Chlorothiazide Chlorthalidone Hydrochlorothiazide Hydroflumethiazide Indapamide Metolazone Nitrofurantoin Nitroglycerin Polythiazide Trichlormethiazide

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]FDA DailyMed · 048b4bc7-c77e-40… · revised December 19, 2024 [PDF]
[2]MHRA (UK) · PL252580108 · revised May 23, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

USOfficial regulatory label· Adverse reactions· revised December 19, 2024[1]

2%). gov/medwatch. 1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of trospium chloride tablets was evaluated in controlled clinical trials in a total of 2975 patients, who were treated with trospium chloride tablets (N=1673), placebo (N=1056) or active control medications (N=246). , efficacy and safety studies and a 9-month open-label extension.
Of this total, 591 patients received trospium chloride tablets 20 mg twice daily. In all controlled trials combined, 232 and 208 patients received treatment with trospium chloride tablets for at least 24 and 52 weeks, respectively. 5% among patients receiving placebo.
S. safety and efficacy trials were reported by at least 1% of patients, and were reported more frequently in the trospium chloride tablets group than in the placebo group. The two most common adverse reactions reported by patients receiving trospium chloride tablets 20 mg twice daily were dry mouth and constipation.
8% of patients receiving placebo. S. 9% of patients treated with trospium chloride tablets 20 mg twice daily. For the patients who reported dry mouth, most had their first occurrence of the event within the first month of treatment. Table 1.
0% of trospium chloride tablets treated patients, and more common with trospium chloride tablets than placebo are: tachycardia , vision blurred, abdominal distension, vomiting, dysgeusia, dry throat, and dry skin. During controlled clinical studies, one adverse reaction of angioneurotic edema was reported.
2 Post-marketing Experience The following adverse reactions have been identified during post-approval use of trospium chloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Gastrointestinal – gastritis; Cardiovascular – palpitations, supraventricular tachycardia, chest pain, syncope, “hypertensive crisis”; Immunological – Stevens-Johnson syndrome, anaphylactic reaction, angioedema; Nervous System – dizziness, confusion, vision abnormal, hallucinations, somnolence and delirium; Musculoskeletal – rhabdomyolysis; General – rash.

USOfficial regulatory label· Warnings and precautions· revised December 19, 2024[1]

5 WARNINGS AND PRECAUTIONS Trospium chloride tablets should be administered with caution to patients with clinically significant bladder outflow obstruction or gastrointestinal obstructive disorders due to risk of urinary or gastric retention.
3 ) Angioedema of the face, lips, tongue and/or larynx has been reported with trospium chloride. 2 ) In patients with controlled narrow angle glaucoma trospium chloride tablets should be used only with careful monitoring. 4 ) Central Nervous System Effects: Somnolence has been reported with trospium chloride tablets.
5 ). Trospium is substantially excreted by the kidney. The effects of moderate renal impairment on systemic exposure are not known but systemic exposure is likely increased. Therefore, the risk of anticholinergic adverse reactions is expected to be greater in patients with moderate renal impairment.
1 Risk of Urinary Retention Trospium chloride tablets should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention [ see Contraindications (4) ]. 2 Angioedema Angioedema of the face, lips, tongue, and/or larynx has been reported with trospium chloride, the active ingredient in trospium chloride tablets.
In one case, angioedema occurred after the first dose of trospium chloride. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, trospium chloride tablets should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.
3 Decreased Gastrointestinal Motility Trospium chloride tablets should be administered with caution to patients with gastrointestinal obstructive disorders because of the risk of gastric retention [ see Contraindications (4) ]. Trospium chloride tablets, like other antimuscarinic agents, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis.
4 Controlled Narrow-angle Glaucoma In patients being treated for narrow-angle glaucoma, trospium chloride tablets should only be used if the potential benefits outweigh the risks and in that circumstance only with careful monitoring [ see Contraindications (4) ].

This is not medical advice. Consult a qualified healthcare professional.